64282-79-7

Upstream product

• 51638-93-8 (3aR,4R,5R,6aS)-5-Hydroxy-4-((E)-(R)-3-hydroxy-4-phenoxy-but-1-enyl)-hexahydro-cyclopenta[b]furan-2-one 
• 79171-98-5 Biphenyl-4-carboxylic acid (3aR,4R,5R,6aS)-4-((E)-(R)-3-hydroxy-4-phenoxy-but-1-enyl)-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 54347-99-8 (3aR,4R,5R,6aS)-Hexahydro-4-<(E)-(3R)-4-phenoxy-3-<(tetrahydro-2H-pyran-2-yl)oxy>-1-butenyl>-5-<(tetrahydro-2H-pyran-2-yl)oxy>-2H-cyclopentafuran-2-one 
• 286840-19-5 (3aR,4R,5R,6aS)-4-[(E)-(R)-4-Phenoxy-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-5-(tetrahydro-pyran-2-yloxy)-hexahydro-cyclopenta[b]furan-2-ol 
• 40665-68-7 dimethyl (3-phenoxy-2-oxopropyl)phosphonate 
• 2065-23-8 methyl 2-phenoxyacetate 
• 62989-31-5 (Z)-7-[(1R,2R,3R,5S)-5-Hydroxy-2-[(E)-(R)-4-phenoxy-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-3-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hept-5-enoic acid 

Downstream Products

• 54382-74-0 16-phenoxy-ω-tetranor-PGE₂ 

Relevant academic research and scientific papers

N-(Methanesulfonyl)-16-phenoxyprostaglandincarboxamides: Tissue-Selective, Uterine Stimulants

In an effort to develop tissue-selective prostaglandin analogues resistant to the metabolic inactivating pathways of the natural materials, hybrid compounds modified both at C-1 with a sulfonimide moiety and in the n-amylcarbinol side chain with substituted phenoxy groups were synthesized and evaluated in a variety of in vitro and in vivo models.Several of these analogues exhibited potent, tissue-selective, uterine stimulant activity, a finding subsequently confirmed in clinical studies with one member of this series, N-(methanesulfonyl)-16-phenoxy-ω-tetranor-PGE2-carboxamide (CP-34089/ZK-57671, sulprostone).